Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Arcus Biosciences, Inc. (RCUS)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Cost of goods sold | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross profit | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Selling, general and administrative | 350.0% | 85.9% | 259.0% | | | | |
| Research and development | | | | 523.2% | 594.3% | 3341.7% | |
| General and administrative | | | | 168.2% | 162.4% | 540.4% | |
| EBITDA | -214.3% | 15.7% | -152.6% | -575.6% | -623.5% | -3626.7% | |
| Depreciation | 5.4% | 1.0% | 3.8% | 23.9% | 43.9% | 184.9% | |
| EBIT | -219.6% | 14.6% | -156.4% | -591.4% | -656.8% | -3782.1% | |
| Pre-tax income | -237.5% | 14.4% | -157.7% | -564.7% | -593.7% | -3756.7% | |
| Income taxes | 0.9% | 0.5% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net income | -238.4% | 13.8% | -157.7% | -564.7% | -593.7% | -3756.7% | |
|